Protect Pharmaceutical Corp (OTC:PRTT) Stock Continues to Trend Higher

This past Friday, Protect Pharmaceutical Corp. (OTC:PRTT) was one of the companies that came into the news cycle after its president, Ali Yildiz, addressed the shareholders through a letter. He started off by stating that the company was in the last stages of its PCOAB audit, and completion was imminent.

He went on to reveal that the company expected to receive the final report soon and hit the goal of completing the audit process before the end of 2023. However, perhaps more importantly, Yildiz stated that as the end of the year approached, it could be said that Protect Pharmaceutical Corp. had accomplished a lot in 2023. The company had experienced growth in both profitability and revenues from one quarter to the next.

Additionally, the company had also been successful in hitting new milestones, which seemed too ambitious in the beginning. Yildiz noted that steady growth was expected to continue in 2024 and went on to state that Protect Pharmaceutical Corp.’s unique strategic positioning in the industry would lead to significant opportunities. Yildis went on to note that the company also launched a stock buyback initiative and would start the program at some point in the upcoming weeks.

The company’s president also noted that he believed that Protect Pharmaceutical was in a strong position to take advantage of some of the developing trends in the industry. The expansion of the company into South America, Eurasia, and the entire European continent would help in maximizing profits. It would help the company scale new heights in terms of profits and revenues. The acquisition of Bosfor Export recently was cited as having opened up fresh opportunities for the company. He went on to note that the acquisition would play a major part in the expansion of the company into South America.